Avitia provides molecular testing solutions to improve cancer treatment, including on-site testing tools and AI-driven bioinformatics. Their platform helps oncologists make more informed treatment decisions based on advanced molecular analysis.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Labs and oncologists often face challenges in obtaining timely and cost-effective molecular testing for cancer, leading to delays in diagnosis and treatment. Sending samples to centralized labs can increase turnaround times and costs, hindering access to personalized treatments, especially in underserved regions.
Solution
Avitia provides an AI-powered platform that enables local labs to perform advanced NGS-based molecular diagnostics on-site, accelerating cancer mutation identification and treatment planning. The platform integrates seamlessly with existing lab systems, reducing testing delays and costs while delivering actionable insights to clinicians. By leveraging AI and machine learning, Avitia tailors diagnostics to regional and patient-specific needs, empowering healthcare teams to deliver faster, more precise, and patient-centric care. The platform supports both tissue and liquid biopsy panels, providing flexibility and operational efficiency for comprehensive cancer testing.
Target Audience
Avitia primarily serves clinical labs, oncologists, and healthcare networks seeking to enhance their cancer diagnostic capabilities with rapid, cost-effective, and AI-powered molecular testing solutions.
Features
- AI-driven bioinformatics platform for accurate cancer mutation identification
- NGS-based tissue and liquid biopsy panels for comprehensive genomic analysis
- Streamlined workflows that integrate with Laboratory Information Management Systems (LIMS) and Electronic Medical Record (EMR) systems
- Secure, cloud-based analytics with prioritized personal health information (PHI) security
- Actionable reporting solutions that identify personalized treatment options and clinical trial matching
- Modular technology system that eliminates the need for proprietary testing kits
- Ability to integrate with comprehensive tests like CGP and low-pass whole genome sequencing
- Distributed partnership model that provides data insights for diverse patient populations